BALTIMORE, April 16, 2025--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...

Tumor necrosis factor (TNF)-α inhibitors are associated with an increased risk of fungal infections, according to the findings of a systematic review published in Mycoses. Investigators explored ...

The use of TNF inhibitors was not linked to worse survival outcomes among patients with rheumatoid arthritis during the 3 years after being diagnosed with lung, colorectal, or prostate cancer.

TNF-α is a potent inducer of the inflammatory response, a key regulator of innate immunity and plays an important role in the regulation of Th1 immune responses against intracellular bacteria and ...

Prime Video, the Smithsonian, Boys & Girls Clubs of America, and NFL Inspire Change are proud to announce a groundbreaking partnership to donate 1 million books and literacy resources to Boys & Girls ...

The incidence rate of herpes zoster in patients treated with conventional DMARDs was 5.6 per 1,000 patient-years, and increased to 11.1 per 1,000 patient-years in those treated with anti-TNF antibody ...

Ustekinumab exhibited higher persistence rates as a second-line therapy than anti–tumour necrosis factor (anti-TNF) treatment in patients with Crohn's disease. Clinical remission rates with ...